Compare TOST & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOST | HOLX |
|---|---|---|
| Founded | 2012 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical Electronics |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 16.6B |
| IPO Year | 2021 | 1990 |
| Metric | TOST | HOLX |
|---|---|---|
| Price | $27.73 | $74.81 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 23 | 13 |
| Target Price | $44.86 | ★ $77.89 |
| AVG Volume (30 Days) | ★ 10.8M | 2.6M |
| Earning Date | 02-12-2026 | 01-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.43 | ★ 2.40 |
| Revenue | ★ $5,858,000,000.00 | $4,126,500,000.00 |
| Revenue This Year | $26.19 | $6.74 |
| Revenue Next Year | $20.61 | $5.48 |
| P/E Ratio | $63.47 | ★ $31.08 |
| Revenue Growth | ★ 25.76 | 2.17 |
| 52 Week Low | $26.92 | $51.90 |
| 52 Week High | $49.66 | $75.36 |
| Indicator | TOST | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 28.65 | 49.63 |
| Support Level | $26.92 | $74.50 |
| Resistance Level | $32.17 | $74.99 |
| Average True Range (ATR) | 1.19 | 0.43 |
| MACD | -0.58 | -0.06 |
| Stochastic Oscillator | 10.98 | 82.79 |
Toast is an end-to-end technology platform designed to address the complex needs of the restaurant industry. The company generates point-in-time revenue through sales of its restaurant-grade hardware and recurring revenue in the form of take rates on restaurant transaction volume as well as subscriptions to its software solutions. As of fiscal 2024, the company provided services to 134,000 restaurant locations primarily in the US. Toast's typical customer is a mid-market restaurant generating slightly more than $1 million in revenue annually.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.